YLIU-4-105-1

YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 binds to the ATP-binding pocket of JH1. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner[1].

Product Specifications

CAS Number

[2417685-83-5]

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yliu-4-105-1.html

Concentration

10mM

Purity

99.39

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(C2=NN3C=C(NC(C4CC4)=O)N=C3C=C2)=C(C)C=C1)NC5=CC(C(F)(F)F)=CC(CN6CCN(CC6)CC)=C5

Molecular Formula

C32H34F3N7O2

Molecular Weight

605.65

References & Citations

[1]Arwood ML, et al. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol. 2023 Jun 15;30 (6) :618-631.e12.